Pancreatic cancer and liver metastases: state of the art

Eugen Bellon; Florian Gebauer; Michael Tachezy; Jakob R Izbicki; Maximilian Bockhorn

doi:10.1007/s13304-016-0407-7

Pancreatic cancer and liver metastases

Standard

Pancreatic cancer and liver metastases : state of the art. / Bellon, Eugen; Gebauer, Florian; Tachezy, Michael; Izbicki, Jakob R; Bockhorn, Maximilian.

In: UPDATES SURG, Vol. 68, No. 3, 09.2016, p. 247-251.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Bellon, E, Gebauer, F, Tachezy, M, Izbicki, JR & Bockhorn, M 2016, 'Pancreatic cancer and liver metastases: state of the art', UPDATES SURG, vol. 68, no. 3, pp. 247-251. https://doi.org/10.1007/s13304-016-0407-7

APA

Bellon, E., Gebauer, F., Tachezy, M., Izbicki, J. R., & Bockhorn, M. (2016). Pancreatic cancer and liver metastases: state of the art. UPDATES SURG, 68(3), 247-251. https://doi.org/10.1007/s13304-016-0407-7

Vancouver

Bellon E, Gebauer F, Tachezy M, Izbicki JR, Bockhorn M. Pancreatic cancer and liver metastases: state of the art. UPDATES SURG. 2016 Sep;68(3):247-251. https://doi.org/10.1007/s13304-016-0407-7

Bibtex

@article{f18d20338ae741138e88b799e5985ead,

title = "Pancreatic cancer and liver metastases: state of the art",

abstract = "Pancreatic cancer is still one of the most aggressive oncological diseases with a 5-year mortality rate below 10%. Surgery remains the only curative treatment; however, most patients present with late-stage disease deemed unresectable, either due to extensive local vascular involvement or the presence of distant metastasis. In the detection of hepatic metastases, the current standard is palliative chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or nab-paclitaxel with gemcitabine. Once hepatic metastases are diagnosed, the guidelines do not recommend resection of the primary tumor. Recent findings suggest that some patients with non-resectable diseases initially have survival rates as good as those with initially resectable disease when they are able to undergo surgical resection. Synchronous resection of both the primary tumour as well as the liver metastases may be beneficial and improves the outcome.",

keywords = "Antineoplastic Agents/therapeutic use, Global Health, Hepatectomy, Humans, Liver Neoplasms/epidemiology, Morbidity/trends, Palliative Care/methods, Pancreatectomy, Pancreatic Neoplasms/pathology, Survival Rate/trends",

author = "Eugen Bellon and Florian Gebauer and Michael Tachezy and Izbicki, {Jakob R} and Maximilian Bockhorn",

year = "2016",

month = sep,

doi = "10.1007/s13304-016-0407-7",

language = "English",

volume = "68",

pages = "247--251",

journal = "UPDATES SURG",

issn = "2038-131X",

publisher = "Springer-Verlag Italia",

number = "3",

}

RIS

TY - JOUR

T1 - Pancreatic cancer and liver metastases

T2 - state of the art

AU - Bellon, Eugen

AU - Gebauer, Florian

AU - Tachezy, Michael

AU - Izbicki, Jakob R

AU - Bockhorn, Maximilian

PY - 2016/9

Y1 - 2016/9

N2 - Pancreatic cancer is still one of the most aggressive oncological diseases with a 5-year mortality rate below 10%. Surgery remains the only curative treatment; however, most patients present with late-stage disease deemed unresectable, either due to extensive local vascular involvement or the presence of distant metastasis. In the detection of hepatic metastases, the current standard is palliative chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or nab-paclitaxel with gemcitabine. Once hepatic metastases are diagnosed, the guidelines do not recommend resection of the primary tumor. Recent findings suggest that some patients with non-resectable diseases initially have survival rates as good as those with initially resectable disease when they are able to undergo surgical resection. Synchronous resection of both the primary tumour as well as the liver metastases may be beneficial and improves the outcome.

AB - Pancreatic cancer is still one of the most aggressive oncological diseases with a 5-year mortality rate below 10%. Surgery remains the only curative treatment; however, most patients present with late-stage disease deemed unresectable, either due to extensive local vascular involvement or the presence of distant metastasis. In the detection of hepatic metastases, the current standard is palliative chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or nab-paclitaxel with gemcitabine. Once hepatic metastases are diagnosed, the guidelines do not recommend resection of the primary tumor. Recent findings suggest that some patients with non-resectable diseases initially have survival rates as good as those with initially resectable disease when they are able to undergo surgical resection. Synchronous resection of both the primary tumour as well as the liver metastases may be beneficial and improves the outcome.

KW - Antineoplastic Agents/therapeutic use

KW - Global Health

KW - Hepatectomy

KW - Humans

KW - Liver Neoplasms/epidemiology

KW - Morbidity/trends

KW - Palliative Care/methods

KW - Pancreatectomy

KW - Pancreatic Neoplasms/pathology

KW - Survival Rate/trends

U2 - 10.1007/s13304-016-0407-7

DO - 10.1007/s13304-016-0407-7

M3 - SCORING: Review article

C2 - 27832445

VL - 68

SP - 247

EP - 251

JO - UPDATES SURG

JF - UPDATES SURG

SN - 2038-131X

IS - 3

ER -